Previous 10 | Next 10 |
home / stock / imvt / imvt articles
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Shares of FedEx Corporation (NYSE: F...
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal li...
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 152.8% to $1.09. The company announced the effective date for its reverse stock split after ...
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in toda...
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday. The Dow traded down 1.19% to 33,601...
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withd...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 0.96% to 33,681.79 ...
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s sessio...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...